Could a common drug keep bladder cancer away?
Prevention
Ongoing
This phase II trial tests whether a low-dose version of the drug rapamycin, called eRapa, can prevent bladder cancer from coming back in people who have already been treated for non-muscle invasive bladder cancer. About 166 participants will take eRapa or a placebo daily for one …
Phase: PHASE2 • Sponsor: Robert Svatek • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC